ClinicalTrials.gg
RecruitingNCT06195644GVS on MSUpdated Jan 8, 2024

Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients

A Phase 1 interventional study of Galvanic vestibular stimulation and MovAlyzeR® software from Neuroscript in Cortical Excitability and Multiple Sclerosis, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 20 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-01-08.

Sponsored by Cairo University · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Sep 2023, registered Dec 2023).
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
20 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Multiple Sclerosis by Cairo University — 8 open to participants now, 10 under way, none of them phase 3. Multiple Sclerosis · Cairo University.

Planned enrollment
10th of 20
40 · median 40
Started
2023
with 2 others
Phase 1
Only one
of the 26
Registered
11th of 26
by date

Among the 26 studies in Multiple Sclerosis by Cairo University, this one is the 10th largest by planned enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2023, is the only one in phase 1, and was the 11th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

8 of the 26 studies in Multiple Sclerosis by Cairo University are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 20 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Multiple Sclerosis by Cairo University, or all of them as a file.
02

Study summary

This study will be conducted to investigate the following:

  1. The impact of implementing GVS in MS rehabilitation on cortical excitability.
  2. The influence of GVS on upper limb function in patients diagnosed with MS. Patients will be randomly assigned to a control group (Conventional Physical Therapy program = CPT) and a study group (Galvanic Vestibular Stimulation = GVS in addition to the conventional program) subsequently. CPT will perform moderate intensity aerobic training (arm ergometer) and task oriented hand manipulation training, while GVS will receive Galvanic Vestibular Stimulation will be added to the conventional physical Therapy program.
03

Conditions studied

  • Cortical Excitability
  • Multiple Sclerosis

Browse trials for

Keywords

  • Galvanic Vestibular Stimulation
  • Hand Dexterity
  • Multiple Sclerosis
  • Transcranial magnetic Stimulation
  • Cortical excitability
04

Who can participate

Ages eligible
20 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with ataxic RRMS type of both genders will be recruited. The last MS relapse occurred at least 3 months prior to the study.
  2. Patients' age will range from 20 to 45 years old.
  3. Ambulant Patients who meet the level less than or equal to 5 on EDSS will be recruited.
  4. Patients' score on should be > 26.
  5. Mild or no spasticity (grade 1 or 1+) according to Modified Ashworth Scale.
  6. All patients must at least hold Primary stage certificate of education from one of the Egyptian educational authorities.
  7. All patients can independently sign consent form

Exclusion criteria

Exclusion Criteria:

  • Patients will be excluded if they have:

    1. Moderate to severe auditory or visual or cognitive impairment.
    2. Coexistence of other neurological diagnoses of Central or Peripheral Nervous system (e.g. cerebrovascular stroke, vestibulopathy or polyneuropathy).
    3. History of any problems that hinder conduction of aerobic training or magnetic stimulation (e.g. deep venous thrombosis, shunts and pacemakers).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    GVS group

    Galvanic Vestibular Stimulation in addition to the Conventional Physical Therapy program of moderate intensity aerobic training on cyclic ergometer for upper limb and task oriented training for hand dexterity.

    Device: Galvanic vestibular stimulation · Device: MovAlyzeR® software from Neuroscript · Device: BODYFIT Mini Portable Pedal Home Exerciser (cyclic ergometer)

  • Active comparator
    CPT group

    Conventional Physical Therapy program of moderate intensity aerobic training on cyclic ergometer for upper limb and task oriented training for hand dexterity.

    Device: MovAlyzeR® software from Neuroscript · Device: BODYFIT Mini Portable Pedal Home Exerciser (cyclic ergometer)

Interventions

  • DeviceGalvanic vestibular stimulation

    galvanic current generated by Gymna DUO 200 and delivered through conductive medium (electrode gel) by two small carbon rubber electrodes 3 cm 2 each bilaterally over two mastoid processes for 30 minutes, two times per week for 12 weeks .

  • DeviceMovAlyzeR® software from Neuroscript

    MovAlyzeR® movement analysis software from Neuroscript turns a pen tablet or mouse into a high-quality system for examining movements by a pen, mouse or finger. Hence, it can train and analyze hand dexterity and handwriting using pen tablets such as sentence parameters.

  • DeviceBODYFIT Mini Portable Pedal Home Exerciser (cyclic ergometer)

    stationary upper body pedaling as a moderate intensity aerobic training

06

What researchers measure

Primary outcomes

  1. Cortical changes

    central motor conduction time is the time taken for neural impulses to travel through the central nervous system on their way to the target muscles.

    Time frame: 15 minutes

  2. Upper Limb motor dexterity

    Nine hole peg test 9 HPT

    Time frame: 15-20 minutes

Secondary outcomes

  1. Advanced dexterity (Handwriting analysis) by MovAlyzeR® software

    Time frame: 15-20 minutes

  2. Balance

    Berg Balance scale (BBS) of 14 items graded on 5 scoring system 0= worst and 4= the best ( total 0 = worst performance - Total 56 = Best performance). The lower your score, the more at risk you are for losing your balance. In general, Berg balance scale scores are interpreted as such: 0 to 20: A person with a score in this range will likely need the assistance of a wheelchair to move around safely.

    Time frame: 15-20 minutes

  3. Fatigue

    Fatigue Severity Scale (FSS)is 9-item questionnaire, scored on a 7 point scale with 1 = strongly disagree and 7= strongly agree. The minimum score = 9 and maximum score possible = 63. Higher the score = greater fatigue severity.

    Time frame: 15-20 minutes

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Dec 2024, 15 months after the start.

Of 53 non-industry phase 1 interventional studies under Multiple Sclerosis, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 71. This study's planned 15 months is below that.

Counting every sponsor, half of 92 studies reached it within 30 months; a quarter within 9 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2023
First posted
Jan 8, 2024
StartActual
Sep 3, 2023
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2025
Last update
Jan 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06195644
Lead sponsor
Cairo University
Responsible party
Mohamed Hassanin (Assistant lecturer, Cairo University) — Principal investigator
First posted
Jan 8, 2024
Start date
Sep 3, 2023
Primary completion
Dec 2024 (estimated)
Completion
Dec 2025 (estimated)
Last update
Jan 8, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion